Updated NETs Clinical Trials
Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
-
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Conditions:  Metastatic Prostate Neuroendocrine Carcinoma;  Metastatic Prostate Cancer
Interventions: Â Drug:Â Nivolumab; Â Drug:Â Ipilimumab; Â Drug:Â Carboplatin; Â Drug:Â Cabazitaxel
Sponsors:  Andrew J. Armstrong, MD;  Bristol-Myers Squibb
Recruiting -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Conditions:  VHL Pancreatic Neuroendocrine Tumors;  Von Hippel-Lindau Disease;  Neuroendocrine Tumors
Intervention:  Drug: 68-Gallium DOTATATE
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung
Conditions:  Extrapulmonary Small Cell Neuroendocrine Carcinoma;  Recurrent Extrapulmonary Small Cell Neuroendocrine Carcinoma;  Recurrent Small Cell Neuroendocrine Carcinoma;  Small Cell Neuroendocrine Carcinoma
Interventions:  Biological: Atezolizumab;  Drug: Carboplatin;  Drug: Cisplatin;  Drug: Etoposide;  Other: Patient Observation
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Conditions:  Small-cell Lung Cancer;  Neuroendocrine Carcinoma
Interventions: Â Drug:Â Iadademstat; Â Drug:Â Paclitaxel
Sponsor:  Fox Chase Cancer Center
Not yet recruiting -
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Conditions:  EGFR-Mutated Non-Small-Cell Lung Carcinoma;  Small Cell/Neuroendocrine
Interventions: Â Drug:Â Olaparib; Â Drug:Â Durvalumab
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)
Conditions:  Pheochromocytoma/Paraganglioma;  Pancreatic Neuroendocrine Tumor;  Von Hippel-Lindau Disease
Intervention: Â Drug:Â Belzutifan
Sponsor:  Merck Sharp & Dohme LLC
Recruiting -
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Conditions:  Locally Advanced Digestive System Neuroendocrine Carcinoma;  Locally Advanced Pancreatic Neuroendocrine Carcinoma;  Metastatic Digestive System Neuroendocrine Carcinoma;  Metastatic Pancreatic Neuroendocrine Carcinoma;  Refractory Digestive System Neuroendocrine Carcinoma;  Refractory Pancreatic Neuroendocrine Carcinoma;  Unresectable Digestive System Neuroendocrine Carcinoma;  Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions:  Drug: Fluorouracil;  Drug: Leucovorin;  Drug: Liposomal Irinotecan;  Procedure: Quality-of-Life Assessment
Sponsors:  Roswell Park Cancer Institute;  Ipsen
Recruiting -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Conditions:  Atypical Carcinoid Tumor;  Carcinoid Tumor;  Functioning Pancreatic Neuroendocrine Tumor;  Intermediate Grade Lung Neuroendocrine Neoplasm;  Locally Advanced Pancreatic Neuroendocrine Tumor;  Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm;  Low Grade Lung Neuroendocrine Neoplasm;  Lung Atypical Carcinoid Tumor;  Lung Carcinoid Tumor;  Metastatic Digestive System Neuroendocrine Neoplasm;  Metastatic Digestive System Neuroendocrine Tumor G1;  Metastatic Pancreatic Neuroendocrine Tumor;  Metastatic Thymic Neuroendocrine Neoplasm;  Neuroendocrine Neoplasm;  Non-Functioning Pancreatic Neuroendocrine Tumor;  Pancreatic Serotonin-Producing Neuroendocrine Tumor;  Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;  Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;  Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions:  Drug: Cabozantinib S-malate;  Other: Laboratory Biomarker Analysis;  Other: Placebo Administration;  Other: Quality-of-Life Assessment
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Conditions:  Locally Advanced Neuroendocrine Neoplasm;  Metastatic Neuroendocrine Neoplasm
Interventions:  Drug: Placebo Administration;  Other: Questionnaire Administration;  Drug: Telotristat Ethyl
Sponsors:  M.D. Anderson Cancer Center;  TerSera Therapeutics LLC
Recruiting -
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Conditions:  Gastroenteropancreatico Tumors;  Neuroendocrine Tumors;  Neuroendocrine Neoplasms
Interventions:  Drug: Lu-177-DOTATATE;  Drug: Olaparib;  Diagnostic Test: Ga dotatate scanning;  Diagnostic Test: FDG-PET scanning
Sponsor:  National Cancer Institute (NCI)
Not yet recruiting -
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Conditions:  SCLC;  Small Cell Cancer;  Advanced Solid Tumor;  High Grade Neuroendocrine Cancers
Interventions: Â Drug:Â Lurbinectedin; Â Drug:Â Berzosertib
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Conditions:  Gastroenteropancreatic Neuroendocrine Tumors;  Pheochromocytoma;  Paraganglioma
Intervention:  Drug: Lutetium [177Lu] oxodotreotide/dotatate
Sponsor:  Advanced Accelerator Applications
Recruiting -
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Conditions:  Advanced Adrenal Gland Pheochromocytoma;  Advanced Paraganglioma;  Metastatic Adrenal Gland Pheochromocytoma;  Metastatic Paraganglioma;  Unresectable Adrenal Gland Pheochromocytoma;  Unresectable Paraganglioma
Interventions:  Drug: Olaparib;  Other: Quality-of-Life Assessment;  Drug: Temozolomide
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
Conditions:  Advanced Solid Tumor;  Metastatic Solid Tumor;  Urothelial Carcinoma;  Large Cell Neuroendocrine Carcinoma of the Lung;  Homologous Recombination Deficiency
Intervention: Â Drug:Â Lurbinectedin
Sponsor:  Jazz Pharmaceuticals
Recruiting -
Hormone Secretion in Transgender Males
Conditions: Â Transgender; Â Healthy
Interventions:  Drug: Testosterone Cyp 200Mg/Ml Inj (in Oil);  Drug: Letrozole
Sponsor:  University of California, San Diego
Not yet recruiting -
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Conditions:  Locally Advanced Solid Tumor;  Metastatic Solid Tumor
Intervention: Â Drug:Â JBI-802
Sponsor:  Jubilant Therapeutics Inc.
Recruiting -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Conditions:  Pheochromocytoma;  Paraganglioma;  Neuroendocrine Tumors;  Neuroendocrine Neoplasms
Interventions:  Drug: Lu-177-DOTATATE;  Drug: Ga-68-DOTATATE;  Drug: F-18-FDG;  Drug: Amino Acid solution
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Conditions:  Bile Duct Cancer;  Gall Bladder Cancer;  Breast Cancer;  Neuroendocrine Tumors;  Ovarian Cancer;  Pancreatic Adenocarcinoma;  Soft Tissue Sarcoma;  Vulvar Cancer;  Prostate Cancer
Interventions: Â Drug:Â Atezolizumab; Â Drug:Â Tivozanib
Sponsors:  University of Florida;  Genentech, Inc.;  Aveo Oncology Pharmaceuticals
Recruiting -
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
Condition:  Advanced Ovarian Cancer
Interventions:  Drug: Ropivacaine;  Drug: Saline Solution
Sponsors:  Karolinska Institutet;  Skane University Hospital
Recruiting -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Conditions:  Bladder Adenocarcinoma;  Bladder Clear Cell Adenocarcinoma;  Bladder Mixed Adenocarcinoma;  Bladder Neuroendocrine Carcinoma;  Bladder Small Cell Neuroendocrine Carcinoma;  Bladder Squamous Cell Carcinoma;  Bladder Urachal Adenocarcinoma;  Chromophobe Renal Cell Carcinoma;  Collecting Duct Carcinoma;  Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;  Infiltrating Bladder Urothelial Carcinoma;  Infiltrating Bladder Urothelial Carcinoma With Giant Cells;  Infiltrating Bladder Urothelial Carcinoma, Nested Variant;  Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;  Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;  Kidney Medullary Carcinoma;  Large Cell Neuroendocrine Carcinoma;  Metastatic Bladder Carcinoma;  Metastatic Bladder Large Cell Neuroendocrine Carcinoma;  Metastatic Bladder Small Cell Neuroendocrine Carcinoma;  Metastatic Bladder Squamous Cell Carcinoma;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;  Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;  Metastatic Kidney Medullary Carcinoma;  Metastatic Malignant Genitourinary System Neoplasm;  Metastatic Penile Carcinoma;  Metastatic Prostate Small Cell Neuroendocrine Carcinoma;  Metastatic Sarcomatoid Renal Cell Carcinoma;  Metastatic Urethral Carcinoma;  Papillary Renal Cell Carcinoma;  Sarcomatoid Renal Cell Carcinoma;  Stage IV Bladder Cancer AJCC v8;  Stage IV Penile Cancer AJCC v8;  Stage IV Prostate Cancer AJCC v8;  Stage IV Renal Cell Cancer AJCC v8;  Stage IV Urethral Cancer AJCC v8;  Stage IVA Bladder Cancer AJCC v8;  Stage IVA Prostate Cancer AJCC v8;  Stage IVB Bladder Cancer AJCC v8;  Stage IVB Prostate Cancer AJCC v8;  Testicular Leydig Cell Tumor;  Testicular Sertoli Cell Tumor;  Urethral Clear Cell Adenocarcinoma
Interventions:  Drug: Cabozantinib S-malate;  Biological: Ipilimumab;  Biological: Nivolumab
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Non-Viral TCR Gene Therapy
Conditions:  Endocrine/Neuroendocrine;  Non-Small Cell Lung Cancer;  Breast Cancer;  Gastrointestinal/Genitourinary Cancers;  Ovarian Cancer
Interventions:  Drug: Fludarabine;  Drug: Cyclophosphamide;  Drug: Aldesleukin;  Biological: Sleeping Beauty Transposed PBL
Sponsor:  National Cancer Institute (NCI)
Recruiting -
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Condition:  Metastic Thyroid Cancer
Intervention: Â Drug:Â 68-Gallium-DOTATATE-PET/CT
Sponsor: Â National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Conditions:  Endocrine Tumors;  Non-Small Cell Lung Cancer;  Ovarian Cancer;  Breast Cancer;  Gastrointestinal/Genitourinary Cancers;  Neuroendocrine Tumors;  Multiple Myeloma
Interventions:  Drug: Cyclophosphamide;  Drug: Fludarabine;  Drug: Aldesleukin;  Biological: Individual Patient TCR-Transduced PBL;  Drug: Pembrolizumab (KEYTRUDA )
Sponsor:  National Cancer Institute (NCI)
Recruiting -
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Condition:  Medullary Thyroid Cancer
Interventions: Â Drug:Â Selpercatinib; Â Drug:Â Cabozantinib; Â Drug:Â Vandetanib
Sponsors:  Loxo Oncology, Inc.;  Eli Lilly and Company
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions:  Advanced Cancer;  Anal Carcinoma;  Anal Cancer;  Biliary Cancer;  Cholangiocarcinoma;  Bile Duct Cancer;  Neuroendocrine Tumor;  Carcinoid Tumor;  Endometrial Carcinoma;  Endometrial Cancer;  Cervical Carcinoma;  Cervical Cancer;  Vulvar Carcinoma;  Vulvar Cancer;  Small Cell Lung Carcinoma;  Small Cell Lung Cancer (SCLC);  Mesothelioma;  Thyroid Carcinoma;  Thyroid Cancer;  Salivary Gland Carcinoma;  Salivary Gland Cancer;  Salivary Cancer;  Parotid Gland Cancer;  Advanced Solid Tumors;  Colorectal Carcinoma
Intervention: Â Biological:Â pembrolizumab
Sponsor:  Merck Sharp & Dohme LLC
Recruiting -
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Conditions:  Locally Advanced Solid Tumors;  Metastatic Solid Tumors
Intervention:  Drug: Oral repotrectinib (TPX-0005)
Sponsors:  Turning Point Therapeutics, Inc.;  Zai Lab (Shanghai) Co., Ltd.
Recruiting -
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Conditions:  Atypical Teratoid/Rhabdoid Tumor;  Epithelioid Sarcoma;  Kidney Medullary Carcinoma;  Malignant Solid Neoplasm;  Poorly Differentiated Chordoma;  Recurrent Atypical Teratoid/Rhabdoid Tumor;  Recurrent Chordoma;  Recurrent Epithelioid Sarcoma;  Recurrent Kidney Medullary Carcinoma;  Recurrent Rhabdoid Tumor;  Refractory Atypical Teratoid/Rhabdoid Tumor;  Refractory Chordoma;  Refractory Epithelioid Sarcoma;  Refractory Kidney Medullary Carcinoma;  Refractory Rhabdoid Tumor;  Rhabdoid Tumor
Interventions: Â Biological:Â Atezolizumab; Â Biological:Â Tiragolumab
Sponsor:  National Cancer Institute (NCI)
Not yet recruiting -
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Conditions:  Non-Small Cell Lung Cancer;  Medullary Thyroid Cancer;  Colon Cancer;  Any Solid Tumor
Intervention: Â Drug:Â LOXO-292
Sponsors:  Loxo Oncology, Inc.;  Eli Lilly and Company
Recruiting -
L19IL2/L19TNF in Skin Cancer Patients
Conditions:  BCC - Basal Cell Carcinoma;  SCC - Squamous Cell Carcinoma;  Merkel Cell Carcinoma;  Keratoacanthoma of Skin;  Malignant Adnexal Tumors of the Skin (MATS);  Tumors From Cutaneous T-cell Lymphoma (CTCL);  Kaposi Sarcoma
Intervention: Â Drug:Â L19IL2/L19TNF
Sponsor:  Philogen S.p.A.
Not yet recruiting -
CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
Conditions:  Merkel Cell Carcinoma;  Cutaneous Squamous Cell Carcinoma;  Metastatic Cancer;  Triple Negative Breast Cancer;  Advanced Cancer
Interventions: Â Drug:Â CMP-001; Â Drug:Â cemiplimab-rwlc
Sponsors:  Checkmate Pharmaceuticals;  Regeneron Pharmaceuticals
Recruiting -
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
Conditions:  Advanced Renal Cell Carcinoma;  Chromophobe Renal Cell Carcinoma;  Clear Cell Renal Cell Carcinoma;  Collecting Duct Carcinoma;  Kidney Medullary Carcinoma;  Metastatic Malignant Neoplasm in the Bone;  Papillary Renal Cell Carcinoma;  Stage IV Renal Cell Cancer AJCC v8;  Unclassified Renal Cell Carcinoma
Interventions:  Drug: Cabozantinib S-malate;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration;  Radiation: Radium Ra 223 Dichloride
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Adjuvant Avelumab in Merkel Cell Cancer
Conditions:  Stage III Merkel Cell Carcinoma AJCC v8;  Stage IIIB Merkel Cell Carcinoma AJCC v8;  Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions:  Drug: Avelumab;  Other: Peripheral Blood Collection;  Other: Placebo
Sponsors:  University of Washington;  EMD Serono
Recruiting -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions:  Adenoid Cystic Skin Carcinoma;  Adnexal Carcinoma;  Anaplastic Large Cell Lymphoma, ALK-Negative;  Anaplastic Large Cell Lymphoma, ALK-Positive;  Apocrine Carcinoma;  Cylindrocarcinoma;  Digital Papillary Adenocarcinoma;  Endocrine Mucin-Producing Sweat Gland Carcinoma;  Extramammary Paget Disease;  Extraocular Cutaneous Sebaceous Carcinoma;  Hidradenocarcinoma;  Keratoacanthoma;  Malignant Sweat Gland Neoplasm;  Merkel Cell Carcinoma;  Microcystic Adnexal Carcinoma;  NK-Cell Lymphoma, Unclassifiable;  Papillary Adenocarcinoma;  Porocarcinoma;  Primary Cutaneous Mucinous Carcinoma;  Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;  Recurrent T-Cell Non-Hodgkin Lymphoma;  Refractory Anaplastic Large Cell Lymphoma;  Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;  Refractory Merkel Cell Carcinoma;  Refractory Mycosis Fungoides;  Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;  Refractory Skin Squamous Cell Carcinoma;  Refractory T-Cell Non-Hodgkin Lymphoma;  Sezary Syndrome;  Signet Ring Cell Carcinoma;  Skin Basal Cell Carcinoma;  Skin Basosquamous Cell Carcinoma;  Skin Squamous Cell Carcinoma;  Spiradenocarcinoma;  Squamoid Eccrine Ductal Carcinoma;  Squamous Cell Carcinoma of Unknown Primary;  Sweat Gland Carcinoma;  Trichilemmal Carcinoma;  Vulvar Squamous Cell Carcinoma
Interventions:  Other: Laboratory Biomarker Analysis;  Biological: Nivolumab;  Biological: Talimogene Laherparepvec
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study
Conditions:  Adrenal Gland Pheochromocytoma;  Hematopoietic and Lymphoid Cell Neoplasm;  Malignant Solid Neoplasm;  Paraganglioma
Interventions: Â Drug:Â Talazoparib; Â Drug:Â Temozolomide
Sponsor:  National Cancer Institute (NCI)
Recruiting -
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Condition:  Neurofibromatosis Type 2
Interventions: Â Drug:Â REC-2282; Â Drug:Â Placebo
Sponsor:  Recursion Pharmaceuticals Inc.
Recruiting -
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Condition:  Merkel Cell Carcinoma
Interventions: Â Drug:Â KRT-232; Â Drug:Â Avelumab
Sponsor:  Kartos Therapeutics, Inc.
Recruiting -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2
Conditions:  Neurofibromatosis Type 2;  Vestibular Schwannoma;  Non-vestibular Schwannoma;  Meningioma;  Ependymoma
Intervention: Â Drug:Â Brigatinib
Sponsors:  Scott R. Plotkin, MD, PhD;  Takeda;  The Children's Tumor Foundation
Recruiting -
Study of Aspirin in Patients With Vestibular Schwannoma
Conditions:  Vestibular Schwannoma;  Acoustic Neuroma;  Neurofibromatosis 2
Interventions: Â Drug:Â Aspirin; Â Drug:Â Placebo
Sponsors:  Massachusetts Eye and Ear Infirmary;  United States Department of Defense;  Massachusetts General Hospital
Recruiting -
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Conditions:  Central Nervous System Nongerminomatous Germ Cell Tumor;  Choriocarcinoma;  Embryonal Carcinoma;  Immature Teratoma;  Malignant Teratoma;  Mixed Germ Cell Tumor;  Pineal Region Germ Cell Tumor;  Pineal Region Immature Teratoma;  Pineal Region Yolk Sac Tumor;  Suprasellar Germ Cell Tumor
Interventions:  Drug: Carboplatin;  Drug: Etoposide;  Biological: Filgrastim;  Drug: Ifosfamide;  Drug: Mesna;  Biological: Pegfilgrastim;  Procedure: Peripheral Blood Stem Cell Transplantation;  Other: Questionnaire Administration;  Radiation: Radiation Therapy;  Procedure: Second-Look Surgery;  Drug: Thiotepa
Sponsors:  Children's Oncology Group;  National Cancer Institute (NCI)
Recruiting